221 related articles for article (PubMed ID: 32747372)
1. Response assessment and outcome of combining immunotherapy and radiosurgery for brain metastasis from malignant melanoma.
Le Rhun E; Wolpert F; Fialek M; Devos P; Andratschke N; Reyns N; Regli L; Dummer R; Mortier L; Weller M
ESMO Open; 2020 Aug; 5(4):. PubMed ID: 32747372
[TBL] [Abstract][Full Text] [Related]
2. Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma.
Chen L; Douglass J; Kleinberg L; Ye X; Marciscano AE; Forde PM; Brahmer J; Lipson E; Sharfman W; Hammers H; Naidoo J; Bettegowda C; Lim M; Redmond KJ
Int J Radiat Oncol Biol Phys; 2018 Mar; 100(4):916-925. PubMed ID: 29485071
[TBL] [Abstract][Full Text] [Related]
3. Combined Immunotherapy and Stereotactic Radiotherapy Improves Neurologic Outcomes in Patients with Non-small-cell Lung Cancer Brain Metastases.
Enright TL; Witt JS; Burr AR; Yadav P; Leal T; Baschnagel AM
Clin Lung Cancer; 2021 Mar; 22(2):110-119. PubMed ID: 33281062
[TBL] [Abstract][Full Text] [Related]
4. Local tumor response and survival outcomes after combined stereotactic radiosurgery and immunotherapy in non-small cell lung cancer with brain metastases.
Singh C; Qian JM; Yu JB; Chiang VL
J Neurosurg; 2019 Feb; 132(2):512-517. PubMed ID: 30771783
[TBL] [Abstract][Full Text] [Related]
5. Immune checkpoint inhibition in patients treated with stereotactic radiation for brain metastases.
Kowalski ES; Remick JS; Sun K; Alexander GS; Khairnar R; Morse E; Cherng HR; Berg LJ; Poirier Y; Lamichhane N; Becker S; Chen S; Molitoris JK; Kwok Y; Regine WF; Mishra MV
Radiat Oncol; 2020 Oct; 15(1):245. PubMed ID: 33109224
[TBL] [Abstract][Full Text] [Related]
6. Toxicity and time lapse between immunotherapy and stereotactic radiotherapy of brain metastases.
Cabanie C; Biau J; Durando X; Mansard S; Molnar I; Chassin V; Verrelle P; Khalil T; Lapeyre M; Dupic G
Cancer Radiother; 2021 Jul; 25(5):432-440. PubMed ID: 33836954
[TBL] [Abstract][Full Text] [Related]
7. A Comparative Retrospective Study of Immunotherapy RANO
Chen X; Lim-Fat MJ; Qin L; Li A; Bryant A; Bay CP; Gao L; Miskin N; Liu Z; Iorgulescu JB; Xu X; Reardon DA; Young GS
Front Oncol; 2021; 11():679331. PubMed ID: 34249718
[TBL] [Abstract][Full Text] [Related]
8. Immune Checkpoint Inhibitor-Induced Cerebral Pseudoprogression: Patterns and Categorization.
Urban H; Steidl E; Hattingen E; Filipski K; Meissner M; Sebastian M; Koch A; Strzelczyk A; Forster MT; Baumgarten P; Ronellenfitsch MW; Steinbach JP; Voss M
Front Immunol; 2021; 12():798811. PubMed ID: 35046955
[TBL] [Abstract][Full Text] [Related]
9. The role of stereotactic radiotherapy in addition to immunotherapy in the management of melanoma brain metastases: results of a systematic review.
Lancellotta V; Del Regno L; Di Stefani A; Fionda B; Marazzi F; Rossi E; Balducci M; Pampena R; Morganti AG; Mangoni M; Lebbe C; Garbe C; Longo C; Schinzari G; Tagliaferri L; Peris K
Radiol Med; 2022 Jul; 127(7):773-783. PubMed ID: 35606609
[TBL] [Abstract][Full Text] [Related]
10. MRI characteristics in treatment for cerebral melanoma metastasis using stereotactic radiosurgery and concomitant checkpoint inhibitors or targeted therapeutics.
Rauch M; Tausch D; Stera S; Blanck O; Wolff R; Meissner M; Urban H; Hattingen E
J Neurooncol; 2021 May; 153(1):79-87. PubMed ID: 33761055
[TBL] [Abstract][Full Text] [Related]
11. Survival Benefit of Stereotactic Radiotherapy in the Complex Management of Metastatic Melanoma.
Kelemen G; Együd Z; Dobi Á; Varga L; Kószó R; Borzási E; Paczona V; Végváry Z; Borzák F; Fodor E; Ócsai H; Baltás E; Oláh J; Hideghéty K
Anticancer Res; 2024 Jan; 44(1):205-212. PubMed ID: 38159978
[TBL] [Abstract][Full Text] [Related]
12. The incidence of radiation necrosis following stereotactic radiotherapy for melanoma brain metastases: the potential impact of immunotherapy.
Kaidar-Person O; Zagar TM; Deal A; Moschos SJ; Ewend MG; Sasaki-Adams D; Lee CB; Collichio FA; Fried D; Marks LB; Chera BS
Anticancer Drugs; 2017 Jul; 28(6):669-675. PubMed ID: 28368903
[TBL] [Abstract][Full Text] [Related]
13. The combination of stereotactic radiosurgery with immune checkpoint inhibition or targeted therapy in melanoma patients with brain metastases: a retrospective study.
Martins F; Schiappacasse L; Levivier M; Tuleasca C; Cuendet MA; Aedo-Lopez V; Gautron Moura B; Homicsko K; Bettini A; Berthod G; Gérard CL; Wicky A; Bourhis J; Michielin O
J Neurooncol; 2020 Jan; 146(1):181-193. PubMed ID: 31836957
[TBL] [Abstract][Full Text] [Related]
14. Potential role for LINAC-based stereotactic radiosurgery for the treatment of 5 or more radioresistant melanoma brain metastases.
Frakes JM; Figura NB; Ahmed KA; Juan TH; Patel N; Latifi K; Sarangkasiri S; Strom TJ; Chinnaiyan P; Rao NG; Etame AB
J Neurosurg; 2015 Nov; 123(5):1261-7. PubMed ID: 26140482
[TBL] [Abstract][Full Text] [Related]
15. Robotic Stereotactic Radiosurgery in Melanoma Patients with Brain Metastases under Simultaneous Anti-PD-1 Treatment.
Trommer-Nestler M; Marnitz S; Kocher M; Rueß D; Schlaak M; Theurich S; von Bergwelt-Baildon M; Morgenthaler J; Jablonska K; Celik E; Ruge MI; Baues C
Int J Mol Sci; 2018 Sep; 19(9):. PubMed ID: 30205431
[TBL] [Abstract][Full Text] [Related]
16. Early imaging radioresponsiveness of melanoma brain metastases as a predictor of patient prognosis.
Zubatkina I; Ivanov P
J Neurosurg; 2018 Aug; 129(2):354-365. PubMed ID: 28841116
[TBL] [Abstract][Full Text] [Related]
17. Melanoma brain metastasis: the impact of stereotactic radiosurgery, BRAF mutational status, and targeted and/or immune-based therapies on treatment outcome.
Kotecha R; Miller JA; Venur VA; Mohammadi AM; Chao ST; Suh JH; Barnett GH; Murphy ES; Funchain P; Yu JS; Vogelbaum MA; Angelov L; Ahluwalia MS
J Neurosurg; 2018 Jul; 129(1):50-59. PubMed ID: 28799876
[TBL] [Abstract][Full Text] [Related]
18. Treatment Monitoring of Immunotherapy and Targeted Therapy Using
Galldiks N; Abdulla DSY; Scheffler M; Wolpert F; Werner JM; Hüllner M; Stoffels G; Schweinsberg V; Schlaak M; Kreuzberg N; Landsberg J; Lohmann P; Ceccon G; Baues C; Trommer M; Celik E; Ruge MI; Kocher M; Marnitz S; Fink GR; Tonn JC; Weller M; Langen KJ; Wolf J; Mauch C
J Nucl Med; 2021 Apr; 62(4):464-470. PubMed ID: 32887757
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of Standard Response Assessment in Neuro-Oncology, Modified Response Assessment in Neuro-Oncology, and Immunotherapy Response Assessment in Neuro-Oncology in Newly Diagnosed and Recurrent Glioblastoma.
Youssef G; Rahman R; Bay C; Wang W; Lim-Fat MJ; Arnaout O; Bi WL; Cagney DN; Chang YS; Cloughesy TF; DeSalvo M; Ellingson BM; Flood TF; Gerstner ER; Gonzalez Castro LN; Guenette JP; Kim AE; Lee EQ; McFaline-Figueroa JR; Potter CA; Reardon DA; Huang RY; Wen PY
J Clin Oncol; 2023 Jun; 41(17):3160-3171. PubMed ID: 37027809
[TBL] [Abstract][Full Text] [Related]
20. The abscopal effect: inducing immunogenicity in the treatment of brain metastases secondary to lung cancer and melanoma.
Tracz JA; Donnelly BM; Ngu S; Vojnic M; Wernicke AG; D'Amico RS
J Neurooncol; 2023 May; 163(1):1-14. PubMed ID: 37086369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]